Researcher profile

Dominik Heinzmann

Dominik Heinzmann contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2022arXiv

Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting

In causal inference, the correct formulation of the scientific question of interest is a crucial step. Here we apply the estimand framework to a comparison of the outcomes of patient-level clinical trials and observational data to help structure the clinical question. In addition, we complement the estimand framework with the target trial framework to address specific issues in defining the estimand attributes using observational data and discuss synergies and differences of the two frameworks. Whereas the estimand framework proves useful to address the challenge that in clinical trials and routine clinical practice patients may switch to subsequent systemic therapies after the initially assigned systematic treatment, the target trial framework supports addressing challenges around baseline confounding and the index date. We apply the combined framework to compare long-term outcomes of a pooled set of three previously reported randomized phase 3 trials studying patients with metastatic non-small cell lung cancer receiving front-line chemotherapy (randomized clinical trial cohort) and similar patients treated with front-line chemotherapy as part of routine clinical care (observational comparative cohort). We illustrate the process to define the estimand attributes and select the estimator to estimate the estimand of interest while accounting for key baseline confounders, index date, and receipt of subsequent therapies. The proposed combined framework provides more clarity on the causal contrast of interest and the estimator to adopt and thus facilitates design and interpretation of the analyses.

preprint2021arXiv

Weighted Approach for Estimating Effects in Principal Strata with Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials

This research was motivated by studying anti-drug antibody (ADA) formation and its potential impact on long-term benefit of a biologic treatment in a randomized controlled trial, in which ADA status was not only unobserved in the control arm but also in a subset of patients from the experimental treatment arm. Recent literature considers the principal stratum estimand strategy to estimate treatment effect in groups of patients defined by an intercurrent status, i.e. in groups defined by a post-randomization variable only observed in one arm and potentially associated with the outcome. However, status information might be missing even for a non-negligible number of patients in the experimental arm. For this setting, a novel weighted principal stratum approach is presented: Data from patients with missing intercurrent event status were re-weighted based on baseline covariates and additional longitudinal information. A theoretical justification of the proposed approach is provided for different types of outcomes, and assumptions allowing for causal conclusions on treatment effect are specified and investigated. Simulations demonstrated that the proposed method yielded valid inference and was robust against certain violations of assumptions. The method was shown to perform well in a clinical study with ADA status as an intercurrent event.

preprint2020arXiv

A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies

One of the challenges in the design of confirmatory trials is to deal with uncertainties regarding the optimal target population for a novel drug. Adaptive enrichment designs (AED) which allow for a data-driven selection of one or more pre-specified biomarker subpopulations at an interim analysis have been proposed in this setting but practical case studies of AEDs are still relatively rare. We present the design of an AED with a binary endpoint in the highly dynamic setting of cancer immunotherapy. The trial was initiated as a conventional trial in early triple-negative breast cancer but amended to an AED based on emerging data external to the trial suggesting that PD-L1 status could be a predictive biomarker. Operating characteristics are discussed including the concept of a minimal detectable difference, that is, the smallest observed treatment effect that would lead to a statistically significant result in at least one of the target populations at the interim or the final analysis, respectively, in the setting of AED.